financetom
Business
financetom
/
Business
/
Thermon Q1 revenue down 5.4%, misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Thermon Q1 revenue down 5.4%, misses estimates
Aug 7, 2025 4:58 AM

Overview

* Thermon ( THR ) fiscal Q1 revenue declines 5.4% yr/yr, missing analysts' expectations

* Adjusted EBITDA of $21.2 mln misses analysts' estimates, per LSEG data

* Co repurchased $9.8 mln in shares

Outlook

* Thermon ( THR ) reiterates full-year 2026 revenue guidance of $495 mln to $535 mln

* Company maintains full-year 2026 EPS guidance of $1.35 to $1.57

* Thermon ( THR ) sees adjusted EBITDA for fiscal 2026 at $104 mln to $114 mln

* Company cites secular demand trends as positive drivers for future growth

Result Drivers

* BACKLOG CONVERSION DELAY - $10 mln revenue delayed due to supply chain issues and production delays, per CEO Bruce Thames

* TARIFF IMPACT - Tariff-related market uncertainty contributed to reduced customer demand and lower revenue

* BOOKINGS RECOVERY - Decline in orders in late April due to trade uncertainty, but recovery seen by end of July

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Miss $108.90 $122.50

Revenue mln mln (4

Analysts

)

Q1 Miss $21.20 $22 mln

Adjusted mln (4

EBITDA Analysts

)

Q1 $120.70

Orders mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electrical components & equipment peer group is "buy"

* Wall Street's median 12-month price target for Thermon Group Holdings Inc ( THR ) is $36.00, about 21.6% above its August 6 closing price of $28.23

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abbott Laboratories Closes Acquisition of Exact Sciences
Abbott Laboratories Closes Acquisition of Exact Sciences
Mar 23, 2026
09:25 AM EDT, 03/23/2026 (MT Newswires) -- Abbott Laboratories ( ABT ) said Monday it has completed its acquisition of Exact Sciences ( EXAS ) , making the company its wholly owned subsidiary. Exact Sciences ( EXAS ) shares ceased trading on Nasdaq following the transaction completion, the company said. Abbott shares were 1.6% higher in Monday premarket trading. ...
AMC Theatres Reports Highest Opening for 2026 Weekend With Project Hail Mary Reaching $140 Million
AMC Theatres Reports Highest Opening for 2026 Weekend With Project Hail Mary Reaching $140 Million
Mar 23, 2026
09:27 AM EDT, 03/23/2026 (MT Newswires) -- AMC Theatres (AMC) said Monday the release of Project Hail Mary was the cinema operator's largest opening weekend of the year, and worldwide ticket sales were over $140 million. The Amazon ( AMZN ) MGM-distributed film helped drive the exhibitor's second-highest weekend of 2026 for both domestic and global admissions revenue, 70% higher...
Tarsus Pharmaceuticals Says Lotilaner Gains China Approval, Expects $15 Million Payment
Tarsus Pharmaceuticals Says Lotilaner Gains China Approval, Expects $15 Million Payment
Mar 23, 2026
09:24 AM EDT, 03/23/2026 (MT Newswires) -- Tarsus Pharmaceuticals ( TARS ) said Monday it became eligible to receive a $15 million milestone payment after the regulatory approval of lotilaner ophthalmic solution TP-03 0.25% to treat Demodex blepharitis in China. The company said Grand Pharmaceutical Group, its partner for the development and commercialization of TP-03 in the Greater China region,...
Form 8.3
Form 8.3
Mar 23, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: First Trust Advisors L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved